Faricimab for nAMD: Key Trial Highlights and Case Example

Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.

Related Content:

Shaping the Future of Retinal Vascular Disease Treatment

Anti-VEGF for RVO: The Gold Standard

Faricimab for DME: Durability and Patient Outcomes

Overview of Real-World Outcomes for nAMD, DME, and RVO Patients